Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer
Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies. Mount Sinai has …
FDA Adds Kantaro’s Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
COVID-SeroKlir is a high-performance test that detects the presence and precise level of SARS-CoV-2 IgG antibodies NEW YORK, Feb. 10, 2021 — Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX /NASDAQ: RNLX), and manufacturing partner …
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
Kantaro’s COVID-SeroKlir and COVID-SeroIndex are high-performing tests that detect the presence and precise level of neutralizing antibodies¹ First and only quantitative COVID-19 antibody tests that do not require proprietary equipment NEW YORK, Feb. 8, 2021 — Kantaro Biosciences, LLC, a joint venture …
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
COVID-SeroKlir is a high-performance semi-quantitative antibody test kit based on Mount Sinai technology, with a broad range of applications in the fight against COVID-19 The Kantaro test is being manufactured at scale and immediately available in the U.S. NEW YORK, Nov. 25, 2020 /PRNewswire/ …
Trellus Health Secures $5M Seed Funding to Transform Care for Chronic Conditions
Collaborates with Mount Sinai to deliver resilience-driven, connected care, integrating expert clinical and behavioral health for better outcomes Trellus Health, a resilience-driven digital health solution for chronic conditions, today announced that it has raised $5 million of seed funding to transform the way chronic …
Bio-Techne and Kantaro Biosciences to Launch a Quantitative Research Use Only COVID-19 Serology Test
Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a …
Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
Development funded under contract award from NIAID/NIH as part of the CIVICs program Currently no approved universal influenza vaccine CDC estimates 35.5 million people were infected with influenza in U.S. during 2018-2019 season Collaboration will combine Dynavax’s CpG 1018 with influenza antigens designed to protect against …
Mount Sinai Health System and Renalytix Form Joint Venture, Kantaro Biosciences, To Develop and Scale Production of COVID Antibody Test Kits
Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution; Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July Mount Sinai Health System (“Mount Sinai”) and RenalytixAI (LSE: RENX) today announced …
Mount Sinai’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From U.S. Food and Drug Administration
Today, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers …
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise. NEW YORK, NY, CAMBRIDGE, MA, ROTTERDAM, NL, and SUZHOU, CN – Mount Sinai Health System and Harbour BioMed (HBM) have …